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Liver TransplantationLowered ImmuneCell Function in Liver Recipients
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Introduction. Tolerance after treatment and recovery from posttransplant lymphoproliferative disease (PTLD) have been de-
scribed but little is known about the immunology. The objective of this study is to evaluate the immunity of pediatric recipients
who recovered from PTLD.Materials andMethods. Pediatric recipients who recovered from PTLD after liver transplant
and twice the number of recipients who never had PTLD were recruited. Their immune statuses were measured by
ImmuKnow (measurement of adenosine 5-triphospate level produced CD4+ T helper cells), and the results were divided into
3 groups, “low” (≤225 ng/mL), “moderate” (226 to 524 ng/mL), and “high” (≥525 ng/mL). The results of both groups were com-
pared and analyzed. Results. Nine PTLD recipients and 20 non-PTLD recipients were recruited. There were no significant
differences in terms of sex and age between the 2 groups. The majority of PTLD recipients (88.9%) had “low” immune status
responses, and none of them had “high” responses. For non-PTLD recipients, more than half (55%) had “moderate” immune
status responses. The median value of adenosine 5-triphospate levels was significantly lower in the PTLD group (119 ng/mL vs
380.5 ng/mL P = 0.014), and their trough immunosuppressant level was also lower (3.8 μg/L vs 7.7 μg/L; P = 0.004). None of
the patients in either group had abnormal liver enzymes (aspartate aminotransferase/alanine aminotransferase) to suggest
graft rejection. Conclusions. Patients who recovered from PTLD have a lower CD4 T-cell activity compared with those
who have not suffered from PTLD. Under careful monitoring, their immunosuppressant levels can be kept at low levels
to prevent recurrence of PTLD.
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Copyright © 2016 The Authors. Transplantation DiPosttransplant lymphoproliferative disorder (PTLD) is alife-threatening complication of immunosuppression and
occurred in 1% to 20% of solid organ transplant recipients.1,2
The incidence of PTLD in adults after liver transplantation
varies from about 1% to 3% in the literature.3,4 In pediatric
patients, a higher incidence of up to 6% to 20% was noted,
largely attributed to the pretransplant Epstein-Barr virus sero-
negativity status in this group of patients.5-8 The incidences are
also believed to correlate with the dosage of immunosuppres-
sion for each type of organ transplant.9
Immune tolerance after treatment and recovery from PTLD
in a small proportion of recipients had been described. Some
recipients are even able to wean off from immunosuppres-
sant.10,11 The immunity of the recipients who survived PTLD
however is largely unclear. An immunoassay named ImmuKnow
(Cylex, Columbia, MD) has been developed and designed to
measure global cell-mediated immunity in immunosuppressed
populations.12,13 This assay is approved by the US Food and
Drug Administration. It is able to measure the ability of CD4+
T helper cells to respond to mitogen activation by quantify-
ing the amount of adenosine 5-triphospate (ATP) produced by
CD4+ T helper cells after stimulation. Because ATP is the basicwww.transplantationdirect.com 1
rect. Published by Wolters Kluwer Health, Inc.
TABLE 1.
Comparisons between PTLD and Non-PTLD patients in terms
of demographic, trough immunosuppressant, liver enzyme
and ATP levels
PTLD (n = 9)
Non-PTLD
(n = 20) P
Male:female 0.8 (4:5) 0.8 (9:11) —
Age, mo 84 (28-168) 78 (26-192) 0.05
Posttransplantation, mo 48 (10-120) 70 (8-156) 0.10
Trough immunosuppressant level, μg/L 3.8 (3-5.6) 7.7 (4.2-12) 0.004
Liver enzyme 36 (10-78) 30 (20-62) 0.07
AST, U/L 40 (15-60) 33 (15-50) 0.15
ALT, U/L
ATP level, ng/mL 88.9% (8) 25% (5) 0.006
Low (≤225) 11.1% (1) 55% (11)
Moderate (226-524) 0% (0) 20% (4)
High (≥525)
FIGURE 1. Comparison of median ATP levels between PTLD
and non-PTLD recipients showing a significantly lower level in
the former group.
2 Transplantation DIRECT ■ 2016 www.transplantationdirect.comenergy source of effector functions of immune cells, immune
responses of immune cells can be reported by the amount of
ATP (ng/mL) generated.
The objective of this study is to assess the immune status
of pediatric postliver transplant recipients who recovered from
PTLD and find out whether these recipients are tolerant to
the liver graft. The accidental development of tolerance in
these recipients who recovered from a life-threatening illness
also provides the golden opportunity to understand more
about tolerance in liver transplantation.
MATERIALS AND METHODS
Liver recipients from Queen Mary Hospital who recov-
ered from PTLD (evidence by histological studies of resected
specimens) and twice the number of recipients (control
arm, age-matched with comparable immunosuppression,
and duration from liver transplantation) who never had
PTLD were recruited. Recipients with history of rejection
or transplanted for autoimmune diseases were excluded.
Patients with infectious mononucleosis-like cases but no
histological evidence of PTLD changes were not included.
During the outpatient follow-up of recruited patients and
controls, 3 mL of blood was collected in the same session
of routine blood tests. The blood samples were processed
by the ImmuKnow (Cylex) for measurement of the CD4+
ATP levels. Clinical data of patients were retrieved from
hospital computerized database.
The immune status measured by ImmuKnow will be re-
ported as numerical value and divided into 3 levels. If the
ATP level is below 225 ng/mL, the immune cell response will
be considered as “low.” If the ATP level is between 226 and
524 ng/mL, it will be considered as “moderate” immune cell
response. A level higher than 525 ng/mLwill be considered as
“high” immune cell response.
Statistical analysis was performed using IBM Statistical
Package for Social Science, version 20.0 (SPSS ver 20.0). Con-
tinuous variables were expressed as median (range) and com-
pared using the Mann-Whitney U test. Categorical variables
were compared using the χ2 test. A P value less than 0.05
was considered to be statistically significant. This study has
been approved by the Institutional Review Board of QueenCopyright © 2016 The Authors. Transplantation DMary Hospital/Hong Kong West Cluster (IRB reference
UW12-552).
RESULTS
Of 125 pediatric patients (age, < 18 years) who had under-
gone primary liver transplantation since 1993, 10 patients
recovered from histologically proven PTLD, survived, and
consented to participate in this study. However, a patient
was excluded because she was receiving treatment for recur-
rent disease at the time of study. Twenty age- and sex-matched
control patients were also recruited. The results are summa-
rized in Table 1. There were no significant differences in terms
of sex and age between the 2 groups. The follow-up period
was longer in the non-PTLD group but this was not statisti-
cally significant. For the PTLD group, according to the World
Health Organization classification, 2 patients had early dis-
eases, 6 patients had polymorphic diseases, and 3 patients
had monomorphic diseases (lymphoma-like condition).
Except for 2 patients in the PTLD group, all patients were
taking tacrolimus as the sole immunosuppressant, and the
trough drug level at the time of this study was significantly
lower in the PTLD group (3.8 μg/L vs 7.7 μg/L; P = 0.004).
Three patients in the PTLD groupwere able to wean off from
immunosuppression for longer than 6 months. None of the pa-
tients had abnormal liver enzyme (aspartate aminotransferase/
alanine transaminase). Regarding the ATP level as measured
by ImmuKnow, majority of PTLD recipients (88.9%) had
“low” responses and 11.1% had “moderate” response, and
none of them had “high” response. For non-PTLD recipi-
ents, 25% had “low” response, 55% had “moderate” re-
sponses, and 20% had “high” response. The median value
of ATP level was significantly lower in the PTLD group
(119 ng/mL, range, 36-257 ng/mL vs 380.5 ng/mL, range,
120-651 ng/mL; P = 0.014) (Figure 1).
DISCUSSION
The incidence of PTLD (8%) in the present series is com-
parable to international standard. In this study, we were
able to demonstrate that a lower level of T-cell immunity
is noted in these patients. Therefore, it can be interpreted
that the development of tolerance and less requirement for
immunosuppression in some of these patients maybe a result
of lower T-cell immune response. A definite explanation for
the underlying physiology will need further laboratory study
to answer but this finding has major impact on the clinicalirect. Published by Wolters Kluwer Health, Inc.
© 2016 Wolters Kluwer Chung et al 3management of PTLD patients. Having known about the
low level of T-cell activity in PTLD patients, these patients
can receive a minimal dosage of immunosuppression with
less fear of rejection. It can be seen that the median trough
drug level was also lower in our PTLD patients, and there
was no evidence of rejection (characterized by the normal
liver enzyme levels). Indeed, 3 patients were able to take off
immunosuppression with stable graft function, another evi-
dence to support that a lower dosage of immunosuppressant
should be considered as a safe maintenance therapy to pre-
vent the recurrence of PTLD.
Liver transplant is an established surgical treatment for
end-stage liver disease in adults as well as children. As with
other organ transplantations, allogenic response after en-
graftment has to be suppressed by the proper use of immu-
nosuppression to avoid graft rejection. The recognition of
alloantigen by T cell is always the first step to provoke the
chain of reactions leading to graft rejection. Therefore,
majority of immunosuppressive drugs act on Tcell. The over-
suppression of T cell, however, can occasionally lead to
uncontrolled proliferation of B cell which is the essential
pathogenesis of PTLD.
Posttransplant lymphoproliferative disease was first recog-
nized in the late 1960s and in majority of the cases, an asso-
ciation with Epstein-Barr virus infection was noted.14-16
Other risk factors which have been reported to be associated
with the its development include age of the recipient, older
donors, high levels of immunosuppression, immunosuppres-
sion regimen, degree of HLA mismatching as well as the
use of anti-lymphocyte therapies.17,18 Posttransplant lympho-
proliferative disease is heterogeneous group of lymphopro-
liferative diseases ranging from benign polyclonal B-cell
proliferation to a malignant monoclonal lymphoma.19 The
disease severity has been classified by the World Health Or-
ganization in 2008 and is classified into 4 subtypes: early,
polymorphic, monomorphic (B-cell/T-cell subtype), and clas-
sical Hodgkin lymphoma lesions.20 Because the overuse of
immunosuppressant is the most widely agreed reason for
the development of PTLD, the accepted treatment policy for
this condition is immunosuppression reduction. However, re-
ported overall response rate to the reduction of immunosup-
pression varies, and at most, around 74% of patients will
respond with only one third of them having sustainable re-
sponse.21-25 In addition, it may take a long time before a clin-
ical response is evident, and therefore, adjuvant treatments
and in most cases, anti-CD20 (rituximab) or chemotherapy
will be needed.
Interestingly, it has been reported that some recipients who
recover from PTLDwill develop operational graft tolerance.10
Tolerance is defined as the specific absence of a destructive
immune response to transplanted tissue in the absence of
immunosuppression and can be divided into central and
peripheral. When this happens, immunosuppression can be
withdrawn. Operational tolerance is defined as the absence
of graft dysfunction without the use of immunosuppression.
As mentioned previously, the major reason for rejection and
hence barrier to tolerance is the recipient's endogenous Tcell.
However, little is known about why tolerance or lesser pro-
pensity for rejection (reflected by theminimal use of immuno-
suppression) can develop in some patients after recovery
from PTLD. To answer this question, we attempted to mea-
sure the T-cell immunity in patients with a history of PTLD.Copyright © 2016 The Authors. Transplantation DiImmuKnow is able to measure the ability of CD4+ T helper
cells to respond to mitogen activation by quantifying the
amount of ATP produced by CD4+ T helper cells after stim-
ulation. Because ATP is the basic energy source of effector
functions of immune cells, immune responses of immune cells
can be reported by the amount of ATP (ng/mL) generated.12,13
ImmuKnow has been assessed for the potential use in both
adult and pediatric transplant patients. Some studies have
reported that transplanted patients with “low” immune
cell response might have a higher risk of infection, whereas
patients with “high” immune cell response might have a
higher risk of graft rejection although controversies exist.
Nevertheless, ImmuKnow assay has been recommended for
the monitoring of cell-mediated immunity after solid organ
transplantation.26-30 Because it is always difficult to titrate
the level of immunosuppressant and set a balance between
rejection and recurrent of PTLD, the measurement of T-cell
activity can therefore be taken as an assessment of the likeli-
hood of rejection and guide the use of immunosuppressive
therapy apart from clinical and biochemical monitoring.
Limitations
This study has a few limitations. First, the sample is rela-
tively small but this is just the normal incidence of PTLD in
postliver transplant recipients. A multicenter study would
be required to increase the sample size of similar studies in
the future. Second, the evaluation of tolerance and rejection
was limited to a 1-point analysis. Although a higher incid-
ence of tolerance and less requirement for immunosuppres-
sion in PTLD recipients could be observed in this study, a
direct causal relationship would require a longer follow-up
period to be established. Third, this study only evaluated pe-
diatric patients, and the findings may not be applicable to
adult recipients.
CONCLUSIONS
In conclusion, this study has demonstrated that ImmuKnow
can be used in clinical practice to evaluate the T-cell function in
postliver transplant recipients. Recipients who have recovered
from PTLD had a lower CD4+ ATP level and probably T-cell
activity than non-PTLD recipients. It may be the underlying
reason for the development of tolerance and less requirement
for immunosuppression in some of the patients. However,
the current study is a cross-sectional study only, and further
studies will be required to confirm this relationship. An alter-
native explanation would be the higher sensitivity to immu-
nosuppression in the PTLD patients. No matter what the
underlying pathophysiology is, with the findings in the cur-
rent study, we believe the level of immunosuppression can
be kept low in PTLD recipients to prevent disease recurrence.
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